Core Insights - Danish drugmaker Genmab's experimental drug for a type of blood cancer did not achieve its primary endpoint in a late-stage clinical trial [1] Company Summary - Genmab announced the failure of its experimental drug in a late-stage study, indicating a setback in its development pipeline [1]